title: Association of short tandem repeat polymorphism in the promoter of prostate cancer antigen 3 gene with the risk of prostate cancer.
abstract: BACKGROUND
  PCA3 (prostate cancer antigen 3) gene is one of the most prostate cancer-specific genes at present. Consequently, the prostate-specific expression and the sharp up-regulation of PCA3 mRNA in prostate cancer suggest a unique transcriptional regulation, which possibly can be attributed to promoter polymorphism. In our study, we evaluated whether there is polymorphism in PCA3 promoter region and also assess the association of the polymorphism with prostate cancer.
  
  
  RESULTS
  We designed a specific primer set to screen the promoter of PCA3 gene by polymerase chain reaction (PCR)-based cloning and sequencing with the DNA extracted from peripheral blood samples of prostate cancer (PCa) cases (n = 186) and healthy control cases (n = 135). Genotype-specific risks were estimated as odds ratios (ORs) with associated 95% confidence intervals (CIs) by chi-square test. Possible deviation of the genotype frequencies from controls and PCa cases expected under Hardy-Weinberg equilibrium was assessed by the chi-square test. Short tandem repeat polymorphism of TAAA was found in the promoter region of PCA3 gene, five polymorphisms and eight genotypes were identified. The eight genotypes were divided into three groups: ≤10TAAA, 11TAAA, ≥12TAAA. The group 11TAAA and ≥12TAAA were associated with higher relative risk for prostate cancer than group ≤10TAAA (OR = 1.76, 95%CI = 1.07-2.89[for group 11TAAA]; OR = 5.28, 95%CI = 1.76-15.89[for group ≥12TAAA]).
  
  
  CONCLUSIONS
  The presence of the (TAAA)n short tandem repeat polymorphisms in the PCA3 promoter region may be a risk factor for prostate cancer in the Chinese population.
authors.affiliation: Department of Medical Laboratory, The First Affiliated Hospital of Wenzhou Medical College, Zhejiang, People's Republic of China.
authors.forename: Wu
authors.initials: W
authors.lastname: Zhou
authors.forename: Zhanguo
authors.initials: Z
authors.lastname: Chen
authors.forename: Wangqiang
authors.initials: W
authors.lastname: Hu
authors.forename: Mo
authors.initials: M
authors.lastname: Shen
authors.forename: Xiaoxia
authors.initials: X
authors.lastname: Zhang
authors.forename: Chengdi
authors.initials: C
authors.lastname: Li
authors.forename: Zhiliang
authors.initials: Z
authors.lastname: Wen
authors.forename: Xiuling
authors.initials: X
authors.lastname: Wu
authors.forename: Yuanping
authors.initials: Y
authors.lastname: Hu
authors.forename: Xiaohua
authors.initials: X
authors.lastname: Zhang
authors.forename: Xiuzhi
authors.initials: X
authors.lastname: Duan
authors.forename: Xiucui
authors.initials: X
authors.lastname: Han
authors.forename: Zhihua
authors.initials: Z
authors.lastname: Tao
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm / Q000235:genetics*; D020022:Genetic Predisposition to Disease; D006801:Humans; D008297:Male; D018895:Microsatellite Repeats / Q000235:genetics*; D008875:Middle Aged; D011110:Polymorphism, Genetic / Q000235:genetics*; D011401:Promoter Regions, Genetic / Q000235:genetics*; D011471:Prostatic Neoplasms / Q000453:epidemiology / Q000235:genetics*
chemical_list: D000951:Antigens, Neoplasm; C479341:prostate cancer antigen 3, human